Idorsia Ltd News - 0RQE

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor Ad hoc announcement pursuant to Art. 53...

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor Ad hoc announcement pursuant to Art. 53...

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value Ad hoc announcement pursuant to...

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value Ad hoc announcement pursuant to...

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year 2023...

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year 2023...

Bondholders approve amended terms of the 2024 convertible bonds

Bondholders approve amended terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of...

Bondholders approve amended terms of the 2024 convertible bonds

Bondholders approve amended terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of...

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond Ad hoc announcement pursuant to Art...

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond Ad hoc announcement pursuant to Art...

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension Ad hoc announcement pursuant to Art. 53 LR...

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension Ad hoc announcement pursuant to Art. 53 LR...

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes an invitation to a bondholder meeting Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6...

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes an invitation to a bondholder meeting Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6...

Idorsia publishes a Financial Status required for an upcoming bondholder meeting

Idorsia publishes a Financial Status required for an upcoming bondholder meeting Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Idorsia Ltd (0RQE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

0RQE News

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Bondholders approve amended terms of the 2024 convertible bonds

Bondholders approve amended terms of the 2024 convertible bonds

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes a Financial Status required for an upcoming bondholder meeting

0RQE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Idorsia Ltd (0RQE) News

Idorsia Ltd (0RQE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

0RQE News

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

Bondholders approve amended terms of the 2024 convertible bonds

Bondholders approve amended terms of the 2024 convertible bonds

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes an invitation to a bondholder meeting

Idorsia publishes a Financial Status required for an upcoming bondholder meeting

0RQE Discussion

Your Recent History